2 weeks Ago By ABMN Staff
Proficio Capital Partners LLC purchased a new position in Becton, Dickinson and Company ( NYSE:BDX – Free Report ) in the fourth quarter, Holdings Channel reports. The fund purchased 95,241 shares of the medical instruments supplier’s stock, valued at approximately $21,607,000. Other hedge funds and other institutional investors have also recently bought and sold shares of the company.
Charles Schwab Investment Management Inc. increased its holdings in shares of Becton, Dickinson and Company by 79.0% in the 3rd quarter.
Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after acquiring an additional 1,317,723 shares during the last quarter. Nordea Investment Management AB increased its stake in Becton, Dickinson and Company by 31.
0% during the fourth quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock valued at $647,082,000 after purchasing an additional 673,568 shares during the last quarter. Massachusetts Financial Services Co.
MA raised its holdings in shares of Becton, Dickinson and Company by 9.4% during the third quarter. Massachusetts Financial Services Co.
MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after purchasing an additional 460,440 shares during the period. Vaughan Nelson Investment Management L.P.
bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth about $108,243,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Becton, Dickinson and Company by 62.2% in the 3rd quarter.
The Manufacturers Life Insurance Company now owns 1,107,317 shares of the medical instruments supplier’s stock valued at $266,974,000 after buying an additional 424,487 shares during the period. 86.97% of the stock is owned by institutional investors.
Insider Activity at Becton, Dickinson and Company In related news, EVP Michael David Garrison sold 2,838 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.
54. Following the completion of the sale, the executive vice president now directly owns 6,141 shares of the company’s stock, valued at $1,371,469.53.
This represents a 31.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website .
Also, Director Jeffrey William Henderson purchased 1,500 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was acquired at an average price of $233.62 per share, for a total transaction of $350,430.
00. Following the transaction, the director now owns 8,015 shares of the company’s stock, valued at $1,872,464.30.
The trade was a 23.02 % increase in their position. The disclosure for this purchase can be found here .
Insiders sold 7,363 shares of company stock valued at $1,676,105 over the last 90 days. 0.36% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes Check Out Our Latest Analysis on Becton, Dickinson and Company Becton, Dickinson and Company Stock Up 1.6 % Becton, Dickinson and Company stock opened at $226.43 on Friday.
Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $251.99.
The stock has a market cap of $65.02 billion, a price-to-earnings ratio of 37.61, a PEG ratio of 1.
63 and a beta of 0.35. The company’s 50-day moving average price is $232.
78 and its two-hundred day moving average price is $232.37. The company has a current ratio of 1.
13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.
Becton, Dickinson and Company ( NYSE:BDX – Get Free Report ) last posted its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating analysts’ consensus estimates of $3.
00 by $0.43. Becton, Dickinson and Company had a net margin of 8.
47% and a return on equity of 15.74%. On average, analysts expect that Becton, Dickinson and Company will post 14.
43 EPS for the current fiscal year. Becton, Dickinson and Company declared that its Board of Directors has authorized a share repurchase plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases.
Stock repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued. Becton, Dickinson and Company Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a $1.
04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.
16 annualized dividend and a dividend yield of 1.84%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 69.
10%. Becton, Dickinson and Company Profile ( Free Report ) Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company ( NYSE:BDX – Free Report ). Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.
com's FREE daily email newsletter ..
